Eisai Press Release


Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022
Aug 04, 2022 08:25 JST
Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the modeling simulation of the impact of ApoE4 genotype.
More info..

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
Aug 04, 2022 08:05 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA.
More info..

Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series
Jul 26, 2022 09:27 JST
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002.
More info..

Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022
Jul 26, 2022 08:04 JST
Eisai Co. Ltd announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN2401).
More info..

U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab
Jul 06, 2022 09:12 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab.
More info..

E.Design Insurance and Eisai Enter Into Business Alliance
Jun 28, 2022 09:20 JST
E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving."
More info..

Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
Jun 24, 2022 10:55 JST
Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the elimination of NTDs towards the achievement of a road map for NTDs 2021-2030 launched by the World Health Organization (WHO).
More info..

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
Jun 22, 2022 13:05 JST
Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model.
More info..

Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
Jun 06, 2022 14:05 JST
Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202).
More info..

Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
Jun 03, 2022 15:37 JST
Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States.
More info..

Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
May 27, 2022 11:49 JST
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7.
More info..

Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
May 27, 2022 11:24 JST
Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW).
More info..

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
May 10, 2022 10:23 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway.
More info..

Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
May 10, 2022 10:00 JST
Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin.
More info..

Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
Apr 01, 2022 13:05 JST
Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022.
More info..

Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
Mar 28, 2022 21:38 JST
Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca, Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan.
More info..

Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
Mar 22, 2022 09:21 JST
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually.
More info..

Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
Mar 15, 2022 12:03 JST
Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today.
More info..

Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
Mar 15, 2022 11:00 JST
Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa).
More info..

Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting
Mar 11, 2022 11:15 JST
Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.
More info..

Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500)
Mar 09, 2022 15:06 JST
Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi.
More info..

LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma
Mar 07, 2022 12:50 JST
Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.
More info..

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab
Mar 04, 2022 10:05 JST
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (BAN2401).
More info..

Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Feb 25, 2022 16:26 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA.
More info..

Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
Feb 01, 2022 16:43 JST
Eisai Co., Ltd. announced today that it was selected as the winner of the Tokyo Governor Prize for Corporate Governance of the Year 2021, which is an award program organized by the Japan Association of Corporate Directors (JACD).
More info..

Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Jan 31, 2022 08:47 JST
This marks the first approval for LENVIMA which will be used in combination with KEYTRUDA for advanced RCC in Asia.
More info..

Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases
Jan 28, 2022 11:43 JST
Eisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022.
More info..

Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
Jan 28, 2022 08:40 JST
Biogen Inc. and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer's disease, including details of the study's goal for diverse enrollment and primary endpoint.
More info..

Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
Jan 20, 2022 08:56 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the publication of results from the Phase 3 Study 309/KEYNOTE-775 trial in the January 19, 2022 edition of the New England Journal of Medicine.
More info..

Latest Release


More Latest Release >>